placebo + Omega-3 carboxylic acids + Dapagliflozin + Placebo
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin)
Conditions
T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin)
Trial Timeline
Jan 1, 2015 → Dec 1, 2015
NCT ID
NCT02279407About placebo + Omega-3 carboxylic acids + Dapagliflozin + Placebo
placebo + Omega-3 carboxylic acids + Dapagliflozin + Placebo is a phase 2 stage product being developed by AstraZeneca for T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin). The current trial status is completed. This product is registered under clinical trial identifier NCT02279407. Target conditions include T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin).
What happened to similar drugs?
20 of 20 similar drugs in T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin) were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02279407 | Phase 2 | Completed |
Competing Products
20 competing products in T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin)